What is Relfydess?

Injectables
Written By Dr Emmaline Ashley

We discussed Galderma, a leader in aesthetic innovation, and its release of a liquid version of abobotulinum toxin A (the toxin in Azzalure/Dysport) as Alluziance earlier. But there is something brand new to discuss!

Galderma has unveiled Relfydess™ (RelabotulinumtoxinA), the world’s first ready-to-use liquid neuromodulator developed with proprietary PEARL™ Technology. This groundbreaking product has recently received approval for use in Europe. So what is it, and what sets it apart from the other toxins?

What is Relfydess?

Relfydess™ is an innovative liquid neuromodulator which has been licensed to improve the appearance of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet). Galderma are highlighting their PEARL™ Technology, which they state aids in preserving molecule integrity, delivering a complex-free, highly active formulation optimised for simple volumetric dosing. This eliminates the need for reconstitution, ensuring consistent and reliable results.

What Sets Relfydess Apart?

Unlike traditional botulinum toxins that require reconstitution, Relfydess™ is pre-formulated for convenience and precision. That reduces any potential clinician errors in resconstituting the product with the wrong amounts. It is also purported to work faster, with clinical trials showing that up to 39% of patients noticed results on day one, making it one of the fastest neuromodulators on the market. In addition to this, up to 75% of patients maintained improvements for six months, offering a balance of speed and sustainability.

The Science Behind Relfydess™

The approval of Relfydess™ is backed by the robust READY clinical trial program, comprising over 1,900 participants across four Phase III studies. Relfydess™ demonstrated a responder rate of 96.3% for frown lines and 87.2% for crow’s feet after one month, compared to just 4.5% and 11.9% for placebo. As already discussed, a significant portion of patients reported visible improvements as early as day one. Results were sustained for six months, with nearly a quarter of patients maintaining visible improvements at this point.

These outcomes highlight the superior efficacy and reliability of Relfydess™ compared to some of the traditional neuromodulators.

Looking Ahead

The introduction of Relfydess™ addresses growing demand for advanced, user-friendly aesthetic treatments. Its ease of use and fast-acting results cater to clinicians seeking efficient solutions and patients prioritising convenience without compromising quality. Following this positive European decision and earlier approval in Australia, Galderma is preparing for national launches across 16 European countries. Regulatory applications in additional regions are underway, reflecting the Galderma’s intention for global expansion. We definitely expect to hear more about this treatment in 2025!

Read our summary slides below:

Read more articles about Injectables
What is Relfydess?
Injectables
What is Relfydess?
Injectables

Galderma has unveiled Relfydess™ (RelabotulinumtoxinA), the world’s first ready-to-use liquid neuromodulator developed with proprietary PEARL™ Technology. This groundbreaking product has recently received approval for use in Europe. So what is it, and what sets it apart from the other toxins?.

Injectables
Which Toxin is Which?
Injectables
Which Toxin is Which?
Injectables

For the longest time Botox has dominated the aesthetics market when it comes to botulinum toxin - so much so that its name is ubiquitous and basically synonymous with the treatment. But there are other brands out there, and for the longest time there have been three main ones competing.

However, the past years have seen a plethora of new brands. The different brand names and characteristics become confusing to both patients and clinicians, so we are going to set things straight. Most importantly, for safety reasons it is vital to know which products are licensed for use here in the UK, and how to recognise you are getting illegal or counterfeit products injected.

Injectables
Fillers DON'T Cause Cancer: The Problem with Clickbait Headlines
Injectables
Fillers DON'T Cause Cancer: The Problem with Clickbait Headlines
Injectables

There have been a number of articles and social media posts linking fillers and cancer in the headlines, which I find both misleading and incredibly irresponsible.


Not only is it potentially scaring and upsetting people for clicks and likes, it also contributes to this overall trend we see of science misinformation and a lack of interest in critical appraisal or nuance, because that’s what gets people riled up on social media.

Injectables
Dr Emmaline Ashley
Next

What is Happening with the EU’s New “Ban” on Retinol?